MAPS Public Benefit Corporation Responds to FDA Clinical Hold Letter with Protocol A1V1

In April 2019, MAPS Public Benefit Corporation (MAPS PBC) sent a response to the clinical hold letter received by the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). The clinical hold letter will delay the proposed clinical research.